Loading clinical trials...
Loading clinical trials...
Treatment of Relapsed CBCC, CC and LPIC Lymphoma With FCM Chemotherapy Alone or in Combination With the Monoclonal Anti CD 20 Antibody Rituximab Followed by Anti-CD 20 Maintenance or Observation Only
Conditions
Interventions
FCM
R-FCM
+2 more
Locations
1
Germany
German Low Grade Study Group (Glsg)
Munich, Germany
Start Date
November 1, 1998
Primary Completion Date
June 1, 2001
Completion Date
June 1, 2021
Last Updated
May 7, 2021
NCT06785818
NCT04911478
NCT06425302
NCT02278796
NCT00081809
NCT02376699
Lead Sponsor
Ludwig-Maximilians - University of Munich
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions